search
Back to results

Investigation on the Bidirectional Cortical Neuroprosthetic System (BiCNS)

Primary Purpose

Tetraplegia, Quadriplegia

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
BiCNS
Sponsored by
Johns Hopkins University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Tetraplegia focused on measuring Tetraplegia, Rehabilitation, Brain Computer Interface, Intracortical Microstimulation, Upper extremity prosthetics, Cervical spinal cord injury, Bilateral, Quadriplegia

Eligibility Criteria

22 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Participants must meet all inclusion criteria, verified by medical evaluation, psychological evaluation, and review of medical history. Inclusion criteria include:

  • Participants with C4-C6 tetraplegia from any etiology except neurodegenerative disease (e.g. amyotrophic lateral sclerosis) or active cancer.
  • Complete or incomplete spinal cord injury classified by the American Spinal Injury Association (ASIA) as A or B or C if fewer than three muscle groups in the leg and foot (as identified in the ASIA Impairment Scale) can be contracted
  • Injury more than one year prior to enrollment
  • Participant has a life expectancy of greater than 5 years
  • Meeting surgical safety criteria, including surgical clearance by the participant's primary healthcare provider, study physicians, and any necessary consultants
  • Willingness and ability to provide informed consent
  • Screened by rehabilitation psychologist with a result showing that the participant has a stable psychosocial support system with caregiver capable of monitoring participant throughout the study
  • Ability and willingness to travel to up to fifty miles to study location up to three days per week for the duration of the study
  • Ability to understand and comply with study session instructions
  • Pain well controlled without narcotic medications
  • No other neurological, orthopedic conditions beyond the spinal cord injury
  • Participant consents to the study and still wishes to participate at the time of the study

Exclusion Criteria:

All interested participants will be reviewed for the presence of exclusion criteria by medical evaluation, review of medical history, self (or assistant) report and evaluation by a psychologist. Presence of any of the following criteria will exclude participants from eligibility to participate. In addition, the medical team has the right to withdraw the participant at any time if any of the exclusion criteria emerge and participants can withdraw at any time for any reason. Withdrawal details are outlined below exclusion criteria. Exclusion criteria include:

  • Neurological conditions: Impaired receptive and/or expressive verbal communication skills
  • Presence of memory impairment on the Rey Auditory Verbal Learning Test
  • Intellectual impairment: score of 26 or less on the Mini-Mental State Examination or history of Intelligence Quotient < 80
  • Chronic psychiatric illness, including psychosis and treatment-resistant major depression, as indicated by a diagnosis of Axis I or Axis II on the Symptom Checklist-90-Revised Test
  • Ventilator dependent
  • Implanted devices such as: pacemakers, cardiac defibrillators, spinal cord or vagal nerve stimulators, deep brain stimulators, cochlear implants or any other implantable device incompatible with MRI.
  • History of drug or alcohol dependence in past 24 months
  • Cerebral lesions affecting frontal and parietal lobes
  • Medical conditions contraindicating surgery of a chronically implanted device (e.g. osteomyelitis, diabetes, hepatitis, any autoimmune disease/disorder, epilepsy, skin disorders causing excessive skin sloughing or poor wound healing, blood or cardiac disorder requiring chronic anti-coagulation)
  • Other chronic, unstable medical conditions that could make control unsuitable (such as tremor or spasticity)
  • Presence of pre-surgical findings in anatomical, functional, and/or vascular neuroimaging that makes achieving implant locations within desired risk levels too challenging (to be decided by neurological and neurosurgical team)
  • Prior cranioplasty
  • Inability to undergo MRI or anticipated need for an MRI during the study period
  • Participants with active infections or unexplained fever
  • Participants with other morbid conditions making the implantation of the recording elements unsafe; not limited to: significant pulmonary, cardiovascular, or renal impairments making the surgical procedure unsafe
  • Pregnancy (confirmation through blood test)
  • Nursing an infant, planning to become pregnant, or not using adequate birth control
  • Corrected vision no worse than 20/30
  • HIV or AIDS infection
  • Existing scalp lesions or skin breakdown
  • Chronic oral or intravenous use of steroids or immunosuppressive therapy
  • Active cancer within the past year or requires chemotherapy
  • Uncontrolled autonomic dysreflexia within the past 3 months
  • An implanted ventricular shunt
  • Suicidal ideation within the past 12 months
  • Medications that affect neuroplasticity: neuroleptics, Benzodiazepines (BDZ), Tricyclic Antidepressants (TCA).

Sites / Locations

  • Department of Physical Medicine and RehabilitationRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Surgical implantation of BiCNS

Arm Description

Outcomes

Primary Outcome Measures

Safety of BiCNS: The device is not explanted during 52-week study
This outcome will be considered successful if the device is not explanted during the 52-week period. Explantation of the device prior to the 52-week study period implies that the device is putting the subject at risk (e.g. through a serious infection at implantation site) and therefore must be removed.

Secondary Outcome Measures

Efficacy of BiCNS: Control of one end-effector using neural signals acquired by the BiCNS
One or more participants demonstrate successful control of an assistive device using the action research arm test (ARAT). The ARAT's is a 19 item measure divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement). Performance on each item is rated on a 4-point ordinal scale ranging from: 3) Performs test normally 2) Completes test, but takes abnormally long or has great difficulty 1) Performs test partially 0) Can perform no part of test
Sensory feedback: the participants can perceive environmental information through delivery of intracortical microstimulation (ICMS).
Intracortical microstimulation will be delivered to participants through the BiCNS device. The effect of ICMS will be measured based on participants' verbal reporting of what the stimuli feel like (quality of percepts) and where they appear to be coming from (location of percepts).

Full Information

First Posted
March 31, 2017
Last Updated
July 31, 2023
Sponsor
Johns Hopkins University
search

1. Study Identification

Unique Protocol Identification Number
NCT03161067
Brief Title
Investigation on the Bidirectional Cortical Neuroprosthetic System
Acronym
BiCNS
Official Title
Investigation on the Bidirectional Cortical Neuroprosthetic System
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2017 (Actual)
Primary Completion Date
July 31, 2025 (Anticipated)
Study Completion Date
September 30, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The Bidirectional Cortical Neuroprosthetic System (BiCNS) consists of NeuroPort Microelectrode Array Systems and NeuroPort Electrodes (Sputtered Iridium Oxide Film), Patient Pedestals, the NeuroPort BioPotential Signal Processing System, and the CereStim C96 Programmable Stimulator. The goals of this early feasibility study consist of safety and efficacy evaluations of this device.
Detailed Description
This proposed early feasibility, investigator-initiated study is led by Dr. Pablo A. Celnik, M.D. at Johns Hopkins Medicine (JHM). The Bidirectional Cortical Neuroprosthetic System (BiCNS) consists of modified versions of 510(k) cleared NeuroPort Electrode Array Systems (Blackrock Microsystems, Inc., Salt Lake City, UT) as well as a neurostimulator module (CereStim R96) for long term neural recording and intracortical microstimulation (ICMS) of the brain. The BiCNS is termed bidirectional because it permits both the recording of information from the brain for controlling an end effector device, as well as enabling information regarding that end effector to be returned to the brain in the form of ICMS. "End effector" in this sense is used to mean a physical or virtual device designed to interact with its (physical or virtual) environment. Electrode arrays will be implanted in the brain in pairs, with a pair comprising a recording array and a stimulating array. A total of six NeuroPort arrays, consisting of three array pairs, will be implanted in each study participant. Each pair will consist of an array implanted in primary motor cortex (M1) for recording and an array implanted in primary sensory cortex (S1) for stimulation and/or recording; both arrays in each pair will be connected to a single percutaneous pedestal as an external interface. In each participant, two such array pairs will be implanted in the hand/arm area of M1 and S1 in the dominant brain hemisphere (e.g., the left hemisphere for a right-handed individual). A third pair will be implanted in the hand/arm area of M1 and S1 in non-dominant hemisphere (e.g. right hemisphere for a right handed-individual). The recording arrays implanted in M1 are the NeuroPort microelectrode arrays with platinum (Pt) tips (K070272), whereas the ICMS arrays implanted in S1 are NeuroPort microelectrode arrays with Sputtered Iridium-Oxide Film (SIROF) tips (K110010). The study has Investigational Device Exemption (IDE) approval from FDA to implant these devices for 52 weeks (plus/minus 2 weeks).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tetraplegia, Quadriplegia
Keywords
Tetraplegia, Rehabilitation, Brain Computer Interface, Intracortical Microstimulation, Upper extremity prosthetics, Cervical spinal cord injury, Bilateral, Quadriplegia

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Surgical implantation of BiCNS
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
BiCNS
Other Intervention Name(s)
NeuroPort
Intervention Description
Surgical implantation
Primary Outcome Measure Information:
Title
Safety of BiCNS: The device is not explanted during 52-week study
Description
This outcome will be considered successful if the device is not explanted during the 52-week period. Explantation of the device prior to the 52-week study period implies that the device is putting the subject at risk (e.g. through a serious infection at implantation site) and therefore must be removed.
Time Frame
52 weeks
Secondary Outcome Measure Information:
Title
Efficacy of BiCNS: Control of one end-effector using neural signals acquired by the BiCNS
Description
One or more participants demonstrate successful control of an assistive device using the action research arm test (ARAT). The ARAT's is a 19 item measure divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement). Performance on each item is rated on a 4-point ordinal scale ranging from: 3) Performs test normally 2) Completes test, but takes abnormally long or has great difficulty 1) Performs test partially 0) Can perform no part of test
Time Frame
52 weeks
Title
Sensory feedback: the participants can perceive environmental information through delivery of intracortical microstimulation (ICMS).
Description
Intracortical microstimulation will be delivered to participants through the BiCNS device. The effect of ICMS will be measured based on participants' verbal reporting of what the stimuli feel like (quality of percepts) and where they appear to be coming from (location of percepts).
Time Frame
52 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants must meet all inclusion criteria, verified by medical evaluation, psychological evaluation, and review of medical history. Inclusion criteria include: Participants with C4-C6 tetraplegia from any etiology except neurodegenerative disease (e.g. amyotrophic lateral sclerosis) or active cancer. Complete or incomplete spinal cord injury classified by the American Spinal Injury Association (ASIA) as A or B or C if fewer than three muscle groups in the leg and foot (as identified in the ASIA Impairment Scale) can be contracted Injury more than one year prior to enrollment Participant has a life expectancy of greater than 5 years Meeting surgical safety criteria, including surgical clearance by the participant's primary healthcare provider, study physicians, and any necessary consultants Willingness and ability to provide informed consent Screened by rehabilitation psychologist with a result showing that the participant has a stable psychosocial support system with caregiver capable of monitoring participant throughout the study Ability and willingness to travel to up to fifty miles to study location up to three days per week for the duration of the study Ability to understand and comply with study session instructions Pain well controlled without narcotic medications No other neurological, orthopedic conditions beyond the spinal cord injury Participant consents to the study and still wishes to participate at the time of the study Exclusion Criteria: All interested participants will be reviewed for the presence of exclusion criteria by medical evaluation, review of medical history, self (or assistant) report and evaluation by a psychologist. Presence of any of the following criteria will exclude participants from eligibility to participate. In addition, the medical team has the right to withdraw the participant at any time if any of the exclusion criteria emerge and participants can withdraw at any time for any reason. Withdrawal details are outlined below exclusion criteria. Exclusion criteria include: Neurological conditions: Impaired receptive and/or expressive verbal communication skills Presence of memory impairment on the Rey Auditory Verbal Learning Test Intellectual impairment: score of 26 or less on the Mini-Mental State Examination or history of Intelligence Quotient < 80 Chronic psychiatric illness, including psychosis and treatment-resistant major depression, as indicated by a diagnosis of Axis I or Axis II on the Symptom Checklist-90-Revised Test Ventilator dependent Implanted devices such as: pacemakers, cardiac defibrillators, spinal cord or vagal nerve stimulators, deep brain stimulators, cochlear implants or any other implantable device incompatible with MRI. History of drug or alcohol dependence in past 24 months Cerebral lesions affecting frontal and parietal lobes Medical conditions contraindicating surgery of a chronically implanted device (e.g. osteomyelitis, diabetes, hepatitis, any autoimmune disease/disorder, epilepsy, skin disorders causing excessive skin sloughing or poor wound healing, blood or cardiac disorder requiring chronic anti-coagulation) Other chronic, unstable medical conditions that could make control unsuitable (such as tremor or spasticity) Presence of pre-surgical findings in anatomical, functional, and/or vascular neuroimaging that makes achieving implant locations within desired risk levels too challenging (to be decided by neurological and neurosurgical team) Prior cranioplasty Inability to undergo MRI or anticipated need for an MRI during the study period Participants with active infections or unexplained fever Participants with other morbid conditions making the implantation of the recording elements unsafe; not limited to: significant pulmonary, cardiovascular, or renal impairments making the surgical procedure unsafe Pregnancy (confirmation through blood test) Nursing an infant, planning to become pregnant, or not using adequate birth control Corrected vision no worse than 20/30 HIV or AIDS infection Existing scalp lesions or skin breakdown Chronic oral or intravenous use of steroids or immunosuppressive therapy Active cancer within the past year or requires chemotherapy Uncontrolled autonomic dysreflexia within the past 3 months An implanted ventricular shunt Suicidal ideation within the past 12 months Medications that affect neuroplasticity: neuroleptics, Benzodiazepines (BDZ), Tricyclic Antidepressants (TCA).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pablo A Celnik, MD
Phone
4105022446
Email
pcelnik@jhmi.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Manuel Anaya, MD
Email
manaya1@jhmi.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pablo A Celnik, MD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Physical Medicine and Rehabilitation
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pablo Celnik, MD
Phone
410-502-2420
Email
pcelnik@jhmi.edu
First Name & Middle Initial & Last Name & Degree
Manuel Anaya
Email
manaya@jhmi.edu

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35725741
Citation
Nickl RW, Anaya MA, Thomas TM, Fifer MS, Candrea DN, McMullen DP, Thompson MC, Osborn LE, Anderson WS, Wester BA, Tenore FV, Crone NE, Cantarero GL, Celnik PA. Characteristics and stability of sensorimotor activity driven by isolated-muscle group activation in a human with tetraplegia. Sci Rep. 2022 Jun 20;12(1):10353. doi: 10.1038/s41598-022-13436-2.
Results Reference
derived
PubMed Identifier
34880087
Citation
Fifer MS, McMullen DP, Osborn LE, Thomas TM, Christie B, Nickl RW, Candrea DN, Pohlmeyer EA, Thompson MC, Anaya MA, Schellekens W, Ramsey NF, Bensmaia SJ, Anderson WS, Wester BA, Crone NE, Celnik PA, Cantarero GL, Tenore FV. Intracortical Somatosensory Stimulation to Elicit Fingertip Sensations in an Individual With Spinal Cord Injury. Neurology. 2022 Feb 15;98(7):e679-e687. doi: 10.1212/WNL.0000000000013173. Epub 2021 Dec 8.
Results Reference
derived

Learn more about this trial

Investigation on the Bidirectional Cortical Neuroprosthetic System

We'll reach out to this number within 24 hrs